Table 3.

The number of CDI cases and incidence before, during and after cessation of LP299v administration as a routine prophylaxis in the nephrology and transplantation ward among all patients and patients during immunosuppressive therapy hospitalized in the nephrology and transplantation ward.

	All Hospitalized Patients		Patients on Immunosuppressive Therapy
	(n)	(%)	(n)	(%)
Before introduction of LP299v	18	1.03% ***	12	4.49% **
During prophylaxis of LP299v	2	0.11%	2	0.72%
After cessation of LP299v	14	0.77% **	10	3.4% *

* p < 0.05, ** p < 0.01, *** p < 0.001 vs. incidence during prophylaxis of LP299v.